Primary Membranous Nephropathy (PMN), built on the rare-kidney communities patients trust, and proven on the hardest version of this problem.

Leapcure reaches membranous nephropathy patients through trusted rare-kidney advocacy networks and precision digital, then supports them through PMN's screening hurdles so your sites receive enrollment-ready patients, not referrals that screen-fail.

Talk to our kidney trials teamSee how it works →
70-80%
Of Primary Membranous Nephropathy cases are anti-PLA2R antibody positive
the biomarker our screening is built around
60-day
Pre-launch recruitment head start
we build before First Patient In
48 hrs
To mobilize our rare-kidney advocacy and digital network
at program launch
100%
of referrals pre-screened against protocol eligibility
before they reach your site

Understanding Membranous Nephropathy as a Clinical Trial Indication

Membranous nephropathy is one of the most common causes of nephrotic syndrome in adults, driven by immune deposits along the glomerular basement membrane that lead to heavy proteinuria, swelling, and a progressive risk to kidney function. Most primary cases are autoimmune, and roughly 70 to 80 percent are positive for anti-PLA2R antibodies, a biomarker that increasingly guides both diagnosis and trial eligibility. Because it is a rare disease, eligible patients are few and widely dispersed rather than concentrated where broad campaigns can reach them.

PMN trials are hard to enroll for reasons that compound. Eligibility typically depends on recent kidney biopsy, anti-PLA2R serology, kidney function thresholds, and washout from prior immunosuppression, so a large share of interested patients screen-fail before they reach a site. Many regimens under study involve IV infusions, which can give patients pause unless expectations and monitoring are set early. And because the population is small and relies on a tight network of nephrology clinics, patient communities, and advocacy organizations, generic digital advertising alone rarely surfaces enough qualified candidates.

Leapcure recruits rare-kidney patients through the communities they already trust, supports them through biopsy timing, antibody testing, and washout, and sets infusion expectations in one-to-one conversations before a referral reaches a site. We have proven this model on the adjacent and equally demanding problem of Lupus Nephritis, a biopsy-driven, antibody-screened, multi-country kidney indication, where our advocacy-led approach delivered 44 patient referrals across five countries and outdelivered a larger-budget vendor 22 to 1. Membranous nephropathy is exactly the kind of problem that model is built for.

The Challenge

PMN trials are hard to enroll for reasons that compound: a small, dispersed population, screening hurdles that cause early screen-fails, infusion hesitancy, and a population that generic digital alone rarely reaches.

A rare disease with few, widely dispersed patients

Membranous nephropathy is rare, so eligible patients are few and widely dispersed rather than concentrated where broad campaigns can reach them. Reaching them takes the rare-kidney communities they already trust.

On an adjacent Phase 2 kidney trial, our advocacy-led model reached a dispersed, hard-to-reach population that typical third-party campaigns do not, delivering 44 referrals across 5 countries.

Screening hurdles cause patients to screen-fail early

Eligibility typically depends on recent kidney biopsy, anti-PLA2R serology, kidney function thresholds, and washout from prior immunosuppression, so a large share of interested patients screen-fail before they reach a site.

We pre-screen against biopsy recency, anti-PLA2R serology, kidney function, and washout before any referral, so sites receive enrollment-ready patients.

IV-infusion regimens give patients pause

Many regimens under study involve IV infusions, which can give patients pause unless expectations and monitoring are set early in the process.

We set IV-infusion expectations and monitoring in one-to-one conversations before a referral reaches a site, so hesitancy does not cost a referral.

Generic digital alone rarely surfaces enough candidates

Because the population is small and relies on a tight network of nephrology clinics, patient communities, and advocacy organizations, generic digital advertising alone rarely surfaces enough qualified candidates.

On our completed Phase 2 kidney program, advocacy communities drove over 50% of enrollment activity, and we outdelivered a larger-budget vendor 22 to 1.

Three Channels. One Advocacy-Led Strategy for Your PMN Trial

Every membranous nephropathy study is different. Leapcure deploys the right mix of advocacy, precision digital, and patient support, mapped to your protocol, your sites, your geographies, and your timeline.

1

Start before First Patient In

We build in a 60-day pre-launch head start to test and adapt 1:1 patient geo-targeting, community outreach, and pre-screening questions, and we can mobilize our rare-kidney advocacy and digital network within 48 hours of program launch.

2

Pre-screen and support across the PMN hurdles

Every patient is engaged before site assignment. We assess protocol eligibility, account for biopsy recency, anti-PLA2R testing, kidney function, and washout, and address IV-infusion expectations early. Sites conduct official screening; we ensure the patients who arrive are informed and prepared.

3

Optimize in real time based on site engagement

Channel performance and site contact rates are tracked continuously across regions and rebalanced weekly based on referral quality, site intake capacity, and protocol progress.

Proven on the Hardest Version of This Problem: a Completed Phase 2 Kidney Trial

Challenge Context

Why this case study

We have not yet completed a membranous nephropathy program. We have completed a Phase 2 Lupus Nephritis program, a kidney indication that shares PMN's hardest features: biopsy-driven eligibility, antibody and serology screening, washout windows, a small and dispersed patient population, and multi-country sites. Here is what that looked like.

Indication

Lupus Nephritis, Phase 2 (adjacent kidney indication, presented as proof of method, not a PMN result).

Sponsor

Leading Immunology Sponsor.

Sites

Active sites across the US, Germany, Italy, Poland, and France.

Challenge

Rescue study. A competing vendor with a larger budget had delivered just 2 referrals. Biopsy-driven and complex eligibility, multi-country coordination, and a dispersed, hard-to-reach population requiring advocacy access.

Channels Deployed

Advocacy community outreach activated across regions, precision digital mapped to site capacity, and a patient support model coordinated across five countries.

Results & Metrics

Patients referred

44 patient referrals delivered across 5 countries (US, Germany, Italy, Poland, France).

Vendor comparison

Outdelivered the competing recruitment vendor 22 to 1 (44 vs. 2), entering as a rescue with a smaller budget.

Screened / enrolled

8+ patients screened, ICF signed, and/or enrolled, in a population where typical third-party campaigns have been shown not to reach.

Advocacy contribution

Advocacy communities drove over 50% of enrollment activity. The advocacy network was the primary enrollment engine.

Why it maps to PMN

Same mechanics: kidney biopsy in the eligibility path, antibody/serology-driven screening, washout windows, a small dispersed population, and multi-country sites.

Four Capabilities, Built for Rare-Kidney Recruitment

Leapcure reaches membranous nephropathy patients through a rare-kidney advocacy network, precision digital mapped to site capacity, patient support through PMN's screening hurdles, and answer-engine visibility delivered to your trial.

Rare-Kidney Advocacy Network

  • •We reach membranous nephropathy patients through the rare-kidney advocacy ecosystem and patient communities they already trust, rather than cold lists or one-off email blasts.
  • •Content is co-developed with community partners so research arrives as a trusted option, not an unsolicited pitch.

Precision Digital

  • •Search and social campaigns built around high-intent PMN queries (for example anti-PLA2R antibody test, protein in urine, membranous nephropathy treatment options) across Google, Bing, Quora, and patient-community platforms, targeted by geography and site proximity.
  • •Digital is the supporting channel. It is mapped to site capacity in real time so sites are not overwhelmed and referral quality holds.

Patient Support Through PMN Screening Hurdles

  • •Every referred patient is supported through biopsy timing, anti-PLA2R testing, kidney-function thresholds, and washout, with IV-infusion expectations and monitoring set early so hesitancy does not cost a referral.
  • •Caregivers and family are included where relevant. Sites receive enrollment-ready patients, not referrals that create coordinator work.

AEO / AI-Search Visibility for Your Trial

  • •Patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview questions like "what membranous nephropathy trials am I eligible for?"
  • •We make the trial's information genuinely retrievable through three honest levers: clean server-rendered structure, first-party authority (real data, sourced statistics, named reviewer, last-updated date), and presence in trusted third-party sources such as advocacy organizations and ClinicalTrials.gov.

Built on the Rare-Kidney Communities Patients Trust

Leapcure reaches rare-kidney patients through advocacy organizations and patient communities, not list purchases. The organizations below are examples of the kinds of national, regional, and grassroots communities through which membranous nephropathy patients are reached.

American Kidney Fund (AKF)

Indication-focused kidney support and education, national reach

National Kidney Foundation (NKF)

Therapeutic-area-level organization, broad connections across kidney disease

NephCure Kidney International

Focused on rare kidney and glomerular disease, international perspective

American Association of Kidney Patients (AAKP)

Regional patient engagement, useful for site-level community reach

Membranous Nephropathy Talk

Grassroots PMN patient community, highly engaged members

Rare-kidney KOLs and community leaders

Clinical and community voices who lend trust to research outreach

Living with membranous nephropathy? A clinical trial may be an option.

If you are living with membranous nephropathy, a clinical trial may give you access to investigational treatments not yet widely available. We know that navigating research options can feel overwhelming, especially while you are managing proteinuria, appointments, biopsy results, and the daily reality of a kidney condition. Leapcure's team provides step-by-step support, and we include your family or caregivers wherever that is helpful.

See if a trial may be right for you
Leapcure kangaroo mascot

Leapcure's rare-kidney recruitment team has completed a Phase 2 Lupus Nephritis program, delivering 44 patient referrals across 5 countries and outdelivering a larger-budget vendor 22 to 1. We deploy advocacy, precision digital, patient support, and AEO / AI-search channels adapted to your protocol, and we can mobilize within 48 hours of program launch.

Talk to our kidney trials team